LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company, followed by a discussion with investors at the following investor conferences during the month of March:
- Citi 2011 Global Healthcare Conference, March 2 at 2:30 p.m. ET in New York, NY
- Cowen & Company 31st Annual Health Care Conference, March 7 at 3:15 p.m. ET in Boston, MA
A live webcast of each presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical General Health